360 related articles for article (PubMed ID: 31392600)
1. Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients.
Lovas S; Varga G; Farkas P; Masszi T; Wohner N; Bereczki Á; Adamkovich N; Borbényi Z; Szomor Á; Alizadeh H; Szaleczky E; Wolf K; Schneider T; Plander M; Szendrei T; Csacsovszki O; Csukly Z; Rajnics P; Egyed M; Nagy Z; Rejtő L; Illés Á; Mikala G; Váróczy L
Int J Hematol; 2019 Nov; 110(5):559-565. PubMed ID: 31392600
[TBL] [Abstract][Full Text] [Related]
2. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Vozella F; Siniscalchi A; Rizzo M; Za T; Antolino G; Coppetelli U; Piciocchi A; Andriani A; Annibali O; De Rosa L; Cimino G; La Verde G; De Stefano V; Cantonetti M; di Toritto TC; Petrucci MT
Ann Hematol; 2021 Apr; 100(4):1059-1063. PubMed ID: 33528611
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.
Xu XS; Dimopoulos MA; Sonneveld P; Ho PJ; Belch A; Leiba M; Capra M; Gomez D; Medvedova E; Iida S; Min CK; Schecter J; Jansson R; Zhang L; Sun YN; Clemens PL
Adv Ther; 2018 Nov; 35(11):1859-1872. PubMed ID: 30374808
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma.
Salomon-Perzyński A; Walter-Croneck A; Usnarska-Zubkiewicz L; Dytfeld D; Zielińska P; Wojciechowska M; Hołojda J; Robak P; Pasternak A; Knopińska-Posłuszny W; Hawrylecka D; Wójtowicz M; Szeremet A; Osowiecki M; Mordak-Domagała M; Zaucha JM; Giannopoulos K; Warzocha K; Jamroziak K
Adv Med Sci; 2019 Sep; 64(2):349-355. PubMed ID: 31125864
[TBL] [Abstract][Full Text] [Related]
6. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
Tzogani K; Penninga E; Schougaard Christiansen ML; Hovgaard D; Sarac SB; Camarero Jimenez J; Garcia I; Lafuente M; Sancho-López A; Salmonson T; Gisselbrecht C; Pignatti F
Oncologist; 2018 May; 23(5):594-602. PubMed ID: 29371479
[TBL] [Abstract][Full Text] [Related]
7. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
Lokhorst HM; Plesner T; Laubach JP; Nahi H; Gimsing P; Hansson M; Minnema MC; Lassen U; Krejcik J; Palumbo A; van de Donk NW; Ahmadi T; Khan I; Uhlar CM; Wang J; Sasser AK; Losic N; Lisby S; Basse L; Brun N; Richardson PG
N Engl J Med; 2015 Sep; 373(13):1207-19. PubMed ID: 26308596
[TBL] [Abstract][Full Text] [Related]
8. Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.
Jullien M; Trudel S; Tessoulin B; Mahé B; Dubruille V; Blin N; Gastinne T; Bonnet A; Lok A; Lebourgeois A; Peterlin P; Garnier A; Chevalier P; Guillaume T; Thomaré P; Le Gouill S; Moreau P; Touzeau C
Ann Hematol; 2019 Jun; 98(6):1435-1440. PubMed ID: 30874850
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Lonial S; Weiss BM; Usmani SZ; Singhal S; Chari A; Bahlis NJ; Belch A; Krishnan A; Vescio RA; Mateos MV; Mazumder A; Orlowski RZ; Sutherland HJ; Bladé J; Scott EC; Oriol A; Berdeja J; Gharibo M; Stevens DA; LeBlanc R; Sebag M; Callander N; Jakubowiak A; White D; de la Rubia J; Richardson PG; Lisby S; Feng H; Uhlar CM; Khan I; Ahmadi T; Voorhees PM
Lancet; 2016 Apr; 387(10027):1551-1560. PubMed ID: 26778538
[TBL] [Abstract][Full Text] [Related]
10. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
[TBL] [Abstract][Full Text] [Related]
11. Daratumumab Monotherapy in Heavily Pretreated Asian Patients With Relapsed and Refractory Multiple Myeloma: A Real-world Experience.
Byun JM; Yoon SS; Koh Y; Kim I; Jo J; Park H; Lee JO; Lee J
Anticancer Res; 2019 Sep; 39(9):5165-5170. PubMed ID: 31519629
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
Usmani SZ; Nahi H; Plesner T; Weiss BM; Bahlis NJ; Belch A; Voorhees PM; Laubach JP; van de Donk NWCJ; Ahmadi T; Uhlar CM; Wang J; Feng H; Qi M; Richardson PG; Lonial S
Lancet Haematol; 2020 Jun; 7(6):e447-e455. PubMed ID: 32470437
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the safety and efficacy of daratumumab outside of clinical trials.
Kobayashi H; Tsushima T; Terao T; Abe Y; Miura D; Narita K; Kitadate A; Takeuchi M; Matsue K
Int J Hematol; 2019 Jun; 109(6):665-672. PubMed ID: 30963473
[TBL] [Abstract][Full Text] [Related]
14. FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.
Bhatnagar V; Gormley NJ; Luo L; Shen YL; Sridhara R; Subramaniam S; Shen G; Ma L; Shord S; Goldberg KB; Farrell AT; McKee AE; Pazdur R
Oncologist; 2017 Nov; 22(11):1347-1353. PubMed ID: 28904172
[TBL] [Abstract][Full Text] [Related]
15. Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma.
Beksac M; Aydin Y; Goker H; Turgut M; Besisik SK; Cagirgan S; Tuglular T; Vural F; Yagci M; Alacacioglu I; Aytan P; Goksoy HS; Gulbas Z; Gunes AK; Gurkan E; Hacioglu SK; Karti SS; Kaynar L; Ozdogu H; Paydas S; Solmaz S; Sonmez M; Tekgunduz E; Yildirim R; Ilhan O
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e474-e484. PubMed ID: 32482539
[TBL] [Abstract][Full Text] [Related]
16. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.
Mateos MV; Spencer A; Nooka AK; Pour L; Weisel K; Cavo M; Laubach JP; Cook G; Iida S; Benboubker L; Usmani SZ; Yoon SS; Bahlis NJ; Chiu C; Ukropec J; Schecter JM; Qin X; O'Rourke L; Dimopoulos MA
Haematologica; 2020; 105(2):468-477. PubMed ID: 31221782
[TBL] [Abstract][Full Text] [Related]
17. Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice.
Park SS; Eom HS; Kim JS; Koh Y; Choi CW; Lee JJ; Kim K; Suh C; Lee JH; Min CK;
Jpn J Clin Oncol; 2019 Jan; 49(1):92-95. PubMed ID: 30476124
[TBL] [Abstract][Full Text] [Related]
18. Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population.
Minarik J; Pour L; Maisnar V; Spicka I; Jungova A; Jelinek T; Brozova L; Krhovska P; Scudla V; Hajek R
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2019 Sep; 163(3):279-283. PubMed ID: 30397362
[TBL] [Abstract][Full Text] [Related]
19. Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
Blair HA
Drugs; 2017 Dec; 77(18):2013-2024. PubMed ID: 29127588
[TBL] [Abstract][Full Text] [Related]
20. Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients-Real-World Data From Hungary.
Lovas S; Obajed Al-Ali N; Varga G; Szita V; Alizadeh H; Plander M; Rajnics P; Illés Á; Szemlaky Z; Mikala G; Váróczy L
Pathol Oncol Res; 2022; 28():1610645. PubMed ID: 36262875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
